VEGFA and cancer: Baseline levels of VEGF-A have fail to predict the effectiveness of bevacizumab in most investigations involving multiple cancer types, and the increased levels of VEGF-A was deemed to be indicator of poor prognosis of mCRC regardless of whether bevacizumab was part of the therapy26, 34, 35, 36, 37.